¼¼°èÀÇ ·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã ½ÃÀå º¸°í¼­(2025³â)
Leber Congenital Amaurosis Global Market Report 2025
»óǰÄÚµå : 1730925
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,156,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,898,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,640,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR) 5.9%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 13¾ï 4,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ ¼ºÀåÀº À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, À¯Àü¼º ¸Á¸·Áúȯ À¯º´·ü »ó½Â, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÀÓ»ó½ÃÇè È®´ë, ÇコÄɾî ÁöÃâ Áõ°¡°¡ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â CRISPR ±â¹Ý Ä¡·á¹ýÀÇ ´ëµÎ, ¹ÙÀÌ¿À ±â¼ú ±â¾÷ °£ÀÇ ¿¬°è °­È­, °³º°È­ ÀÇ·á °³¹ß, ¿ø°Ý ¾È°úÀÇ ¼ºÀå, ¸Á¸· È­»ó ±â¼úÀÇ Áøº¸ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

À¯Àü¼º ¸Á¸· ÁúȯÀÇ À¯º´·ü »ó½ÂÀº ·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã(LCA) ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯Àü¼º ¸Á¸·Áúȯ(IRD)Àº ½Ã·ÂÀ» °üÀåÇÏ´Â ´« ¾ÈÂÊÀÇ ±¤°¨¼ö¼º Á¶Á÷ÀÎ ¸Á¸·¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯Àü¼º ÁúȯÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀÇ Áõ°¡´Â À¯ÀüÀÚ °Ë»ç Áøº¸, ÀÎÁöµµ Çâ»ó, Áø´ÜÀÇ Çâ»ó, ¼ö¸í ¿¬Àå¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»çÀÇ Áøº¸·Î IRD Áø´ÜÀÌ ½¬¿öÁ® ´õ ¸¹Àº »ç·Ê°¡ ƯÁ¤µÇ°Ô µÇ¾ú½À´Ï´Ù. ·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã´Â À¯ÀüÀÚ º¯ÀÌ ¹× ÁúȯÀÇ ¸ÞÄ¿´ÏÁòÀ» ¹àÈûÀ¸·Î½á À¯Àü¼º ¸Á¸·ÁúȯÀÇ ÀÌÇØ¸¦ ³ôÀ̰í Ç¥Àû¿ä¹ý°ú Ä¡·áÀÇ °³¹ß¿¡ °øÇåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2025³â 1¿ù ¿µ±¹ ÀÇȸ ÇÏ¿øµµ¼­°ü¿¡ µû¸£¸é 2024³â¿¡´Â ¿µ±¹¿¡¼­ ¾à 2¸¸ 5,000¸íÀÌ À¯Àü¼º ¸Á¸·Áúȯ¿¡ ÀÌȯµÅ ¿¬°£ 2% Áõ°¡¸¦ ³ªÅ¸³»°í ÀÖ½À´Ï´Ù. ±× °á°ú À¯Àü¼º ¸Á¸·ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã ½ÃÀåÀÇ °¢ ȸ»ç´Â ½Ã·Â ȸº¹°ú Áúº´ °ü¸®¸¦ °³¼±Çϱâ À§ÇØ RNA ±â¹Ý Ä¡·á °³¹ß¿¡ Á¡Á¡ ÈûÀ» ½ñ°í ÀÖ½À´Ï´Ù. RNA ±â¹Ý Ä¡·á¹ýÀº RNA ºÐÀÚ¸¦ ÀÌ¿ëÇÏ¿© À¯ÀüÀû °úÁ¤À» Ç¥ÀûÀ¸·Î Çϰí Áúº´À» Ä¡·áÇÕ´Ï´Ù. À̵é Ä¡·á¹ý¿¡´Â mRNA ¹é½Å, siRNA Ä¡·á¹ý, ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å, RNA ¾ÐŸ¸Ó µîÀÌ Æ÷ÇԵ˴ϴÙ. ¿¹¸¦ µé¾î 2025³â 1¿ù ÇÁ¶û½º Á¦¾àȸ»çÀÎ Laboratoires Thea S.A.S.´Â À¯Àü¼º ¸Á¸·Áúȯ RNA ¿ä¹ýÀ» ÃßÁøÇÏ´Â »ç¾÷ºÎ¹®ÀÎ Sepul Bio¸¦ Ãâ¹ü½ÃÄ×½À´Ï´Ù. ¼¼Ç»¸£ ¹ÙÀÌ¿À»ç´Â ƯÈ÷ ·¹º£¸£ ¼±Ãµ¼º Èæ¾Ï½Ã 10(LCA10)¿¡ ´ëÇÑ sepofarsen°ú USH2A °ü·Ã ¸Á¸·»ö¼Òº¯¼ºÁõ¿¡ ´ëÇÑ ultevursenÀ» Ÿ±êÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ultevursenÀÇ LUNA ÆäÀÌÁî 2b ÀÓ»ó½ÃÇè¿¡¼­ ÃÖÃÊÀÇ È¯ÀÚ¿¡ÀÇ Åõ¿©¿¡ ¼º°øÇÑ °ÍÀ» µÎ°í, ¼¼ÆÄ¸£¹ÙÀÌ¿À»ç´Â ÀÌ·¯ÇÑ µå¹® À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ´ëÀÀÀ¸·Î Å©°Ô ÀüÁøÇÒ Å¼¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Leber congenital amaurosis (LCA) is an inherited eye disorder that leads to significant vision impairment or blindness from a young age, caused by genetic mutations that hinder the retina's ability to process light. The condition is marked by weak visual responses, involuntary eye movements (nystagmus), and severe farsightedness due to malfunctioning photoreceptors and gradual retinal degeneration.

Treatment options for LCA primarily include gene therapy, medication, retinal prosthetics, assistive technologies, and other interventions. Gene therapy is a technique that uses genetic material to treat or prevent disorders such as LCA by fixing defective genes. LCA is classified based on the age of onset, including congenital LCA (present at birth), early childhood LCA (1-5 years old), and late-onset LCA (after 6 years). Medications for LCA are distributed through various means such as direct tenders and retail sales, and are used in hospitals, specialized eye clinics, ophthalmology research centers, and home care environments.

The leber congenital amaurosis market research report is one of a series of new reports from The Business Research Company that provides leber congenital amaurosis market statistics, including the leber congenital amaurosis industry global market size, regional shares, competitors with the leber congenital amaurosis market share, detailed leber congenital amaurosis market segments, market trends, and opportunities, and any further data you may need to thrive in the leber congenital amaurosis industry. This leber congenital amaurosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leber congenital amaurosis market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth observed during the historical period can be attributed to factors such as increased awareness of rare eye diseases, greater government funding, enhanced diagnostic methods, the expansion of ophthalmic research centers, and patient advocacy efforts.

The leber congenital amaurosis market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period is expected to be driven by higher investments in gene therapy, the rising prevalence of inherited retinal disorders, regulatory approvals for new treatments, the expansion of clinical trials, and an increase in healthcare spending. Key trends for the forecast period include the rise of CRISPR-based therapies, greater collaboration between biotechnology companies, the development of personalized medicine, the growth of teleophthalmology, and advancements in retinal imaging technologies.

The rising prevalence of inherited retinal diseases is expected to drive the growth of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic disorders that affect the retina, the light-sensitive tissue at the back of the eye responsible for vision. The increase in these diseases can be attributed to advancements in genetic testing, greater awareness, better diagnosis, and longer life expectancy. Progress in genetic testing has made it easier to diagnose IRDs, resulting in more cases being identified. Leber congenital amaurosis has helped enhance the understanding of inherited retinal diseases by revealing genetic mutations and disease mechanisms, contributing to the development of targeted therapies and treatments. For example, according to the UK Parliament's House of Commons Library in January 2025, approximately 25,000 people in the UK were affected by inherited retinal diseases in 2024, marking a 2% annual increase. As a result, the growing prevalence of inherited retinal diseases is driving the growth of the leber congenital amaurosis market.

Companies in the leber congenital amaurosis market are increasingly focusing on developing RNA-based treatments to improve vision restoration and disease management. RNA-based therapies utilize RNA molecules to target genetic processes and treat diseases. These therapies include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Thea S.A.S., a French pharmaceutical company, launched Sepul Bio, a business unit dedicated to advancing RNA therapies for inherited retinal diseases. Sepul Bio is specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is poised to make significant progress in addressing these rare genetic disorders.

In October 2024, Ocuphire Pharma Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition aims to create a leading clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). Opus Genetics Inc. is a US-based company that specializes in developing gene therapies for IRDs.

Major players in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OU, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber congenital amaurosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leber congenital amaurosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leber congenital amaurosis (LCA) market consists of revenues earned by entities by providing services such as clinical trial services, healthcare and patient support services, vision rehabilitation services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber congenital amaurosis (LCA) market also includes sales of retinal implants, diagnostic testing kits, assistive devices, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leber Congenital Amaurosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leber congenital amaurosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for leber congenital amaurosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber congenital amaurosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Leber Congenital Amaurosis Market Characteristics

3. Leber Congenital Amaurosis Market Trends And Strategies

4. Leber Congenital Amaurosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Leber Congenital Amaurosis Growth Analysis And Strategic Analysis Framework

6. Leber Congenital Amaurosis Market Segmentation

7. Leber Congenital Amaurosis Market Regional And Country Analysis

8. Asia-Pacific Leber Congenital Amaurosis Market

9. China Leber Congenital Amaurosis Market

10. India Leber Congenital Amaurosis Market

11. Japan Leber Congenital Amaurosis Market

12. Australia Leber Congenital Amaurosis Market

13. Indonesia Leber Congenital Amaurosis Market

14. South Korea Leber Congenital Amaurosis Market

15. Western Europe Leber Congenital Amaurosis Market

16. UK Leber Congenital Amaurosis Market

17. Germany Leber Congenital Amaurosis Market

18. France Leber Congenital Amaurosis Market

19. Italy Leber Congenital Amaurosis Market

20. Spain Leber Congenital Amaurosis Market

21. Eastern Europe Leber Congenital Amaurosis Market

22. Russia Leber Congenital Amaurosis Market

23. North America Leber Congenital Amaurosis Market

24. USA Leber Congenital Amaurosis Market

25. Canada Leber Congenital Amaurosis Market

26. South America Leber Congenital Amaurosis Market

27. Brazil Leber Congenital Amaurosis Market

28. Middle East Leber Congenital Amaurosis Market

29. Africa Leber Congenital Amaurosis Market

30. Leber Congenital Amaurosis Market Competitive Landscape And Company Profiles

31. Leber Congenital Amaurosis Market Other Major And Innovative Companies

32. Global Leber Congenital Amaurosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leber Congenital Amaurosis Market

34. Recent Developments In The Leber Congenital Amaurosis Market

35. Leber Congenital Amaurosis Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â